Review



murine tumor cell lines ct26  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    ATCC murine tumor cell lines ct26
    Murine Tumor Cell Lines Ct26, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 3500 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murine tumor cell lines ct26/product/ATCC
    Average 99 stars, based on 3500 article reviews
    murine tumor cell lines ct26 - by Bioz Stars, 2026-03
    99/100 stars

    Images



    Similar Products

    99
    ATCC murine tumor cell lines ct26
    Murine Tumor Cell Lines Ct26, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murine tumor cell lines ct26/product/ATCC
    Average 99 stars, based on 1 article reviews
    murine tumor cell lines ct26 - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    99
    ATCC murine ct26 homozygous kras sup g12d sup tumor cell line
    Murine Ct26 Homozygous Kras Sup G12d Sup Tumor Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murine ct26 homozygous kras sup g12d sup tumor cell line/product/ATCC
    Average 99 stars, based on 1 article reviews
    murine ct26 homozygous kras sup g12d sup tumor cell line - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    96
    ATCC murine tumor cell line tc 1
    Murine Tumor Cell Line Tc 1, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murine tumor cell line tc 1/product/ATCC
    Average 96 stars, based on 1 article reviews
    murine tumor cell line tc 1 - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    99
    ATCC b16f10 melanoma murine cancer cell line
    FAT-1 transgenic mice show improved overall survival, lower body mass, and protection against tumor growth compared with WT mice. A, Schematic of the FAT-1 transgenic mouse model. B, Kaplan–Meier curve showing the survival probability of WT and FAT-1 naïve animals. C, Comparison of body weight of WT and FAT-1 animals as they age (****, P < 0.0005). D, Tumor growth kinetics of TC-1 lung cancer cell lines in FAT-1 and WT (*, P < 0.02). E, Kaplan–Meier survival curve for TC-1 lung cancer tumor–bearing WT and FAT-1 mice (**, P < 0.009). F, Tumor growth kinetics of <t>B16F10</t> melanoma cancer cell lines in WT and FAT-1 animals (***, P < 0.0001). G, Kaplan–Meier survival curve for B16F10 melanoma tumor–bearing WT and FAT-1 mice (*, P < 0.002). H, Percentage of tumor-free mice after inoculation in WT vs. FAT-1 in the B16F10 melanoma tumor model (****, P < 0.005). I, Illustration showing the experimental design of BMDC culture and antigen presentation assay in vitro . J, The bar graph showing the frequency of major immune cell types in the spleen of WT vs. FAT-1 mice (orange, stained control; green, FAT-1; blue, WT). K, Levels of IFNγ in supernatant from WT or FAT-1 BMDCs cocultured with CD8 + T cells from PMEL-1 mice measured by ELISA (*, P < 0.008). L, Overlay of expression of major surface markers, including activation and costimulatory markers (CD11b, CD11c, MHC class II, CD40, CD80, CD86) between mature antigen-pulsed BMDCs derived from FAT-1 (green curve) and WT (blue curve) mice. Statistical analysis: Multiple comparisons were made using two-way ANOVA. The Šidák correction test was applied to correct for multiple comparisons. The Mann–Whitney test (unpaired/nonparametric comparing the difference in median) was used as applicable for all figures. EPA, eicosapentaenoic acid; PMA/ION, phorbol 12-myristate 13-acetate/ionomycin.
    B16f10 Melanoma Murine Cancer Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/b16f10 melanoma murine cancer cell line/product/ATCC
    Average 99 stars, based on 1 article reviews
    b16f10 melanoma murine cancer cell line - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    96
    ATCC tumor cells murine eg7 ova tumor cell line
    FAT-1 transgenic mice show improved overall survival, lower body mass, and protection against tumor growth compared with WT mice. A, Schematic of the FAT-1 transgenic mouse model. B, Kaplan–Meier curve showing the survival probability of WT and FAT-1 naïve animals. C, Comparison of body weight of WT and FAT-1 animals as they age (****, P < 0.0005). D, Tumor growth kinetics of TC-1 lung cancer cell lines in FAT-1 and WT (*, P < 0.02). E, Kaplan–Meier survival curve for TC-1 lung cancer tumor–bearing WT and FAT-1 mice (**, P < 0.009). F, Tumor growth kinetics of <t>B16F10</t> melanoma cancer cell lines in WT and FAT-1 animals (***, P < 0.0001). G, Kaplan–Meier survival curve for B16F10 melanoma tumor–bearing WT and FAT-1 mice (*, P < 0.002). H, Percentage of tumor-free mice after inoculation in WT vs. FAT-1 in the B16F10 melanoma tumor model (****, P < 0.005). I, Illustration showing the experimental design of BMDC culture and antigen presentation assay in vitro . J, The bar graph showing the frequency of major immune cell types in the spleen of WT vs. FAT-1 mice (orange, stained control; green, FAT-1; blue, WT). K, Levels of IFNγ in supernatant from WT or FAT-1 BMDCs cocultured with CD8 + T cells from PMEL-1 mice measured by ELISA (*, P < 0.008). L, Overlay of expression of major surface markers, including activation and costimulatory markers (CD11b, CD11c, MHC class II, CD40, CD80, CD86) between mature antigen-pulsed BMDCs derived from FAT-1 (green curve) and WT (blue curve) mice. Statistical analysis: Multiple comparisons were made using two-way ANOVA. The Šidák correction test was applied to correct for multiple comparisons. The Mann–Whitney test (unpaired/nonparametric comparing the difference in median) was used as applicable for all figures. EPA, eicosapentaenoic acid; PMA/ION, phorbol 12-myristate 13-acetate/ionomycin.
    Tumor Cells Murine Eg7 Ova Tumor Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tumor cells murine eg7 ova tumor cell line/product/ATCC
    Average 96 stars, based on 1 article reviews
    tumor cells murine eg7 ova tumor cell line - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    99
    ATCC murine mammary tumor cell line 4t1
    FAT-1 transgenic mice show improved overall survival, lower body mass, and protection against tumor growth compared with WT mice. A, Schematic of the FAT-1 transgenic mouse model. B, Kaplan–Meier curve showing the survival probability of WT and FAT-1 naïve animals. C, Comparison of body weight of WT and FAT-1 animals as they age (****, P < 0.0005). D, Tumor growth kinetics of TC-1 lung cancer cell lines in FAT-1 and WT (*, P < 0.02). E, Kaplan–Meier survival curve for TC-1 lung cancer tumor–bearing WT and FAT-1 mice (**, P < 0.009). F, Tumor growth kinetics of <t>B16F10</t> melanoma cancer cell lines in WT and FAT-1 animals (***, P < 0.0001). G, Kaplan–Meier survival curve for B16F10 melanoma tumor–bearing WT and FAT-1 mice (*, P < 0.002). H, Percentage of tumor-free mice after inoculation in WT vs. FAT-1 in the B16F10 melanoma tumor model (****, P < 0.005). I, Illustration showing the experimental design of BMDC culture and antigen presentation assay in vitro . J, The bar graph showing the frequency of major immune cell types in the spleen of WT vs. FAT-1 mice (orange, stained control; green, FAT-1; blue, WT). K, Levels of IFNγ in supernatant from WT or FAT-1 BMDCs cocultured with CD8 + T cells from PMEL-1 mice measured by ELISA (*, P < 0.008). L, Overlay of expression of major surface markers, including activation and costimulatory markers (CD11b, CD11c, MHC class II, CD40, CD80, CD86) between mature antigen-pulsed BMDCs derived from FAT-1 (green curve) and WT (blue curve) mice. Statistical analysis: Multiple comparisons were made using two-way ANOVA. The Šidák correction test was applied to correct for multiple comparisons. The Mann–Whitney test (unpaired/nonparametric comparing the difference in median) was used as applicable for all figures. EPA, eicosapentaenoic acid; PMA/ION, phorbol 12-myristate 13-acetate/ionomycin.
    Murine Mammary Tumor Cell Line 4t1, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murine mammary tumor cell line 4t1/product/ATCC
    Average 99 stars, based on 1 article reviews
    murine mammary tumor cell line 4t1 - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    99
    ATCC murine cancer cell lines b16 f10 melanoma
    FAT-1 transgenic mice show improved overall survival, lower body mass, and protection against tumor growth compared with WT mice. A, Schematic of the FAT-1 transgenic mouse model. B, Kaplan–Meier curve showing the survival probability of WT and FAT-1 naïve animals. C, Comparison of body weight of WT and FAT-1 animals as they age (****, P < 0.0005). D, Tumor growth kinetics of TC-1 lung cancer cell lines in FAT-1 and WT (*, P < 0.02). E, Kaplan–Meier survival curve for TC-1 lung cancer tumor–bearing WT and FAT-1 mice (**, P < 0.009). F, Tumor growth kinetics of <t>B16F10</t> melanoma cancer cell lines in WT and FAT-1 animals (***, P < 0.0001). G, Kaplan–Meier survival curve for B16F10 melanoma tumor–bearing WT and FAT-1 mice (*, P < 0.002). H, Percentage of tumor-free mice after inoculation in WT vs. FAT-1 in the B16F10 melanoma tumor model (****, P < 0.005). I, Illustration showing the experimental design of BMDC culture and antigen presentation assay in vitro . J, The bar graph showing the frequency of major immune cell types in the spleen of WT vs. FAT-1 mice (orange, stained control; green, FAT-1; blue, WT). K, Levels of IFNγ in supernatant from WT or FAT-1 BMDCs cocultured with CD8 + T cells from PMEL-1 mice measured by ELISA (*, P < 0.008). L, Overlay of expression of major surface markers, including activation and costimulatory markers (CD11b, CD11c, MHC class II, CD40, CD80, CD86) between mature antigen-pulsed BMDCs derived from FAT-1 (green curve) and WT (blue curve) mice. Statistical analysis: Multiple comparisons were made using two-way ANOVA. The Šidák correction test was applied to correct for multiple comparisons. The Mann–Whitney test (unpaired/nonparametric comparing the difference in median) was used as applicable for all figures. EPA, eicosapentaenoic acid; PMA/ION, phorbol 12-myristate 13-acetate/ionomycin.
    Murine Cancer Cell Lines B16 F10 Melanoma, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murine cancer cell lines b16 f10 melanoma/product/ATCC
    Average 99 stars, based on 1 article reviews
    murine cancer cell lines b16 f10 melanoma - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    Image Search Results


    FAT-1 transgenic mice show improved overall survival, lower body mass, and protection against tumor growth compared with WT mice. A, Schematic of the FAT-1 transgenic mouse model. B, Kaplan–Meier curve showing the survival probability of WT and FAT-1 naïve animals. C, Comparison of body weight of WT and FAT-1 animals as they age (****, P < 0.0005). D, Tumor growth kinetics of TC-1 lung cancer cell lines in FAT-1 and WT (*, P < 0.02). E, Kaplan–Meier survival curve for TC-1 lung cancer tumor–bearing WT and FAT-1 mice (**, P < 0.009). F, Tumor growth kinetics of B16F10 melanoma cancer cell lines in WT and FAT-1 animals (***, P < 0.0001). G, Kaplan–Meier survival curve for B16F10 melanoma tumor–bearing WT and FAT-1 mice (*, P < 0.002). H, Percentage of tumor-free mice after inoculation in WT vs. FAT-1 in the B16F10 melanoma tumor model (****, P < 0.005). I, Illustration showing the experimental design of BMDC culture and antigen presentation assay in vitro . J, The bar graph showing the frequency of major immune cell types in the spleen of WT vs. FAT-1 mice (orange, stained control; green, FAT-1; blue, WT). K, Levels of IFNγ in supernatant from WT or FAT-1 BMDCs cocultured with CD8 + T cells from PMEL-1 mice measured by ELISA (*, P < 0.008). L, Overlay of expression of major surface markers, including activation and costimulatory markers (CD11b, CD11c, MHC class II, CD40, CD80, CD86) between mature antigen-pulsed BMDCs derived from FAT-1 (green curve) and WT (blue curve) mice. Statistical analysis: Multiple comparisons were made using two-way ANOVA. The Šidák correction test was applied to correct for multiple comparisons. The Mann–Whitney test (unpaired/nonparametric comparing the difference in median) was used as applicable for all figures. EPA, eicosapentaenoic acid; PMA/ION, phorbol 12-myristate 13-acetate/ionomycin.

    Journal: Cancer Immunology Research

    Article Title: High Levels of Endogenous Omega-3 Fatty Acids Promote Dendritic Cell Antigen Presentation and Improve Dendritic Cell–Based Cancer Vaccine Efficacy in Mice

    doi: 10.1158/2326-6066.CIR-24-0927

    Figure Lengend Snippet: FAT-1 transgenic mice show improved overall survival, lower body mass, and protection against tumor growth compared with WT mice. A, Schematic of the FAT-1 transgenic mouse model. B, Kaplan–Meier curve showing the survival probability of WT and FAT-1 naïve animals. C, Comparison of body weight of WT and FAT-1 animals as they age (****, P < 0.0005). D, Tumor growth kinetics of TC-1 lung cancer cell lines in FAT-1 and WT (*, P < 0.02). E, Kaplan–Meier survival curve for TC-1 lung cancer tumor–bearing WT and FAT-1 mice (**, P < 0.009). F, Tumor growth kinetics of B16F10 melanoma cancer cell lines in WT and FAT-1 animals (***, P < 0.0001). G, Kaplan–Meier survival curve for B16F10 melanoma tumor–bearing WT and FAT-1 mice (*, P < 0.002). H, Percentage of tumor-free mice after inoculation in WT vs. FAT-1 in the B16F10 melanoma tumor model (****, P < 0.005). I, Illustration showing the experimental design of BMDC culture and antigen presentation assay in vitro . J, The bar graph showing the frequency of major immune cell types in the spleen of WT vs. FAT-1 mice (orange, stained control; green, FAT-1; blue, WT). K, Levels of IFNγ in supernatant from WT or FAT-1 BMDCs cocultured with CD8 + T cells from PMEL-1 mice measured by ELISA (*, P < 0.008). L, Overlay of expression of major surface markers, including activation and costimulatory markers (CD11b, CD11c, MHC class II, CD40, CD80, CD86) between mature antigen-pulsed BMDCs derived from FAT-1 (green curve) and WT (blue curve) mice. Statistical analysis: Multiple comparisons were made using two-way ANOVA. The Šidák correction test was applied to correct for multiple comparisons. The Mann–Whitney test (unpaired/nonparametric comparing the difference in median) was used as applicable for all figures. EPA, eicosapentaenoic acid; PMA/ION, phorbol 12-myristate 13-acetate/ionomycin.

    Article Snippet: B16F10 melanoma murine cancer cell line (ATCC, CRL-6475, 2019) was grown in complete RPMI 1640 (cRPMI), comprising RPMI 1640 supplemented with 10% FBS, 100 IU/mL penicillin, 100 μg/mL streptomycin, and 2 mmol/L L-glutamine at 37°C in humidified air with 5% CO 2 .

    Techniques: Transgenic Assay, Comparison, Immunopeptidomics, In Vitro, Staining, Control, Enzyme-linked Immunosorbent Assay, Expressing, Activation Assay, Derivative Assay, MANN-WHITNEY

    FAT-1–derived BMDCs significantly reduce tumor burden in WT B16F10 melanoma tumor–bearing mice. A, Tumor inoculation and vaccination schedule. B, Kaplan–Meier survival curve for vehicle-, WT DC–, and FAT-1 DC–vaccinated B16F10 melanoma tumor–bearing animals. C, Tumor growth kinetic comparison of the vehicle- and WT DC–vaccinated tumor-bearing WT animals. D, Tumor growth kinetic comparison of the vehicle- and FAT-1 DC–vaccinated tumor-bearing WT animals. E–G, Tumor growth rate between day 10 (before vaccine dose 2) and day 17 (before vaccine dose 3) for vehicle-, WT DC–, or FAT-1 DC–vaccinated B16F10 melanoma tumor–bearing animals. H, Proportion of mice with smaller tumors (<600 mm 3 in TC-1 lung cancer and <500 mm 3 in B16F10 melanoma) in different DC vaccine groups in TC-1 lung cancer and B16F10 melanoma tumor–bearing mice. **, P < 0.005; ***, P < 0.0005; NS, nonsignificant. veh, vehicle.

    Journal: Cancer Immunology Research

    Article Title: High Levels of Endogenous Omega-3 Fatty Acids Promote Dendritic Cell Antigen Presentation and Improve Dendritic Cell–Based Cancer Vaccine Efficacy in Mice

    doi: 10.1158/2326-6066.CIR-24-0927

    Figure Lengend Snippet: FAT-1–derived BMDCs significantly reduce tumor burden in WT B16F10 melanoma tumor–bearing mice. A, Tumor inoculation and vaccination schedule. B, Kaplan–Meier survival curve for vehicle-, WT DC–, and FAT-1 DC–vaccinated B16F10 melanoma tumor–bearing animals. C, Tumor growth kinetic comparison of the vehicle- and WT DC–vaccinated tumor-bearing WT animals. D, Tumor growth kinetic comparison of the vehicle- and FAT-1 DC–vaccinated tumor-bearing WT animals. E–G, Tumor growth rate between day 10 (before vaccine dose 2) and day 17 (before vaccine dose 3) for vehicle-, WT DC–, or FAT-1 DC–vaccinated B16F10 melanoma tumor–bearing animals. H, Proportion of mice with smaller tumors (<600 mm 3 in TC-1 lung cancer and <500 mm 3 in B16F10 melanoma) in different DC vaccine groups in TC-1 lung cancer and B16F10 melanoma tumor–bearing mice. **, P < 0.005; ***, P < 0.0005; NS, nonsignificant. veh, vehicle.

    Article Snippet: B16F10 melanoma murine cancer cell line (ATCC, CRL-6475, 2019) was grown in complete RPMI 1640 (cRPMI), comprising RPMI 1640 supplemented with 10% FBS, 100 IU/mL penicillin, 100 μg/mL streptomycin, and 2 mmol/L L-glutamine at 37°C in humidified air with 5% CO 2 .

    Techniques: Derivative Assay, Comparison